Low sensitivity of the careHPV™ Assay for detection of Oncogenic Human Papillomavirus in cervical samples from HIV-infected and HIV-uninfected Kenyan women

Authors:
  • TMTitus M
    Titus M
  • EAErmel A
    Ermel A
  • MAMoormann A
    Moormann A
  • CSCu-Uvin S
    Cu-Uvin S
  • TPTonui P
    Tonui P
  • CKChelimo K
    Chelimo K
  • RBRosen B
    Rosen B
  • IPItsura P
    Itsura P
  • MKMuthoka K
    Muthoka K
  • LPLoehrer P
    Loehrer P
  • OJOng’eCha Jm
    Ong’eCha Jm

Abstract
Background: Human papillomavirus (HPV) infection causes cervical cancer (CC), a common malignancy among Kenyan women. New CC screening methods rely on oncogenic HPV (“high-risk”, or HR-HPV) detection, but most have not been evaluated in swabs from Kenyan women. Methods: HPV typing was performed on 155 cervical swabs from Kenyan women using the Roche Linear Array® (LA) and careHPV™ (careHPV) assays. Detection of 14 oncogenic HPV types in careHPV assay was compared to LA results. Results: Compared to LA, sensitivity and specificity of careHPV assay was 53.0% and 80.9%, respectively. The sensitivity and specificity of careHPV in swabs from women with cervical dysplasia was 74.1% and 65.2%, respectively. The sensitivity and specificity of careHPV in swabs from HIV-infected women was 55.9% and of 96.4%, respectively. Overall agreements of careHPV assay with LA was substantial. Conclusion: The results for careHPV assay are promising for oncogenic HPV detection in Kenyan women. The low sensitivity of careHPV for detection of HR-HPV could limit it’s benefit as a screening tool. Thus, a full clinical validation study is highly desirable before the careHPV assay can be accepted for cervical cancer screening.

This publication has 17 references indexed in Scilit: